I realized this week that Feb. 12 was the 3rd anniversary of the approval of ibrutinib in the USA that changed the whole treatment landscape in CLL, so I thought I would reflect on all the progress that has taken place in the treatment of our disease during this time frame and all the issues that still remain. You can read my thoughts and share your own here: cllsociety.org/2017/02/refl...
What a wild and wonderful three years it has been- but we are not over the finish line quite yet
Stay strong.
We are all in this together.
Brian